drugset / Trial / NCT05515393
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
Phase 2
Unknown
420 enrolled
Shijiazhuang Yiling Pharmaceutical Co. Ltd
First Affiliated Hospital, Sun Yat-Sen University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Overall Design: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-exploration study. Main outcome: 1.To evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke.
Timeline
- Start
- 2022-09-24
- Primary completion
- 2023-12-30
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XY03-EA | Unknown | 300 mg | Oral |
| Subject | XY03-EA | Unknown | 600 mg | Oral |